• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Zydus Lifesciences Limited — Updates, 01-09-2026: General Updates

    01-09-2026 | 10:59 am

    Zydus Lifesciences' FY26 revenues rose 17% to Rs. 27,150 Cr with 31.2% EBITDA. US FDA granted Saroglitazar NDA Priority Review, targeting Q4 FY27 launch. The company declared Re. 1 dividend and approved a Rs. 1,100 Cr share buyback, forecasting high-teen revenue growth for FY27.

    No comments yet. Be the first to comment!

    All announcements from Zydus Lifesciences Limited